Study of Lipid Profile and High Sensitivity C Reactive Protein in Women with Polycystic Ovary Syndrome
Background: This study was undertaken to assess the lipid profile parameters and serum levels of high sensitivity C reactive protein (hsCRP) in women with polycystic ovary syndrome. (PCOS). Methods: 80 women diagnosed with PCOS based on Rotterdam ESHRE/ASRM criteria and 40 age matched healthy controls were selected for the study. Anthropometric and biochemical parameters like serum lipid profile and hsCRP were evaluated among these women. Results: Women with PCOS were found to have significantly higher levels of total cholesterol, triglycerides, LDL-C and hsCRP and significantly lower levels of HDL-C as compared to controls. Conclusions: Targeted screening and timely interventions to reduce cardiovascular risk in women with PCOS is necessary to attenuate the complications of the disease.
2. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab. 2010;95(5):2038-2049.
3. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2(4):232-239.
4. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
5. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia 2009;13(2):90-92.
6. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47.
7. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M et al. Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol. 2006;155(1):131-136.
8. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048-58.
9. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004;89(5):2160-2165.
10. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61(5):946-951.
11. Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem. 2004;50(12): 2316-2322.
12. Verit FF. High sensitive serum C-reactive protein and its relationship with other cardiovascular risk factors in normoinsulinemic polycystic ovary patients without metabolic syndrome. Arch Gynecol Obstet. 2010;281(6):1009-1014.
13. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C - reactive protein, Interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-334.
14. Wu Y, Zhang J, Wen Y, Wang H, Zhang M, Cianflone K. Increased acylation-stimulating protein, C-reactive protein, and lipid levels in young women with polycystic ovary syndrome. Fertil Steril. 2009;91(1):213-219.
15. Al-Youzbaki WB, Abdullah RG. C-reactive protein and lipid profile in patients with polycystic ovary syndrome treated by metformin. Pak J Med Sci 2013;29(2):554-559.
16. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG. Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. Metabolism. 2003;52(6):713-719.
17. Giallauria F, Orio F, Palomba S, Lombardi G, Colao A, Vigorito C. Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown). 2008;9(10):987-992.